Since 2011, however, the rules of the treatment of stage IV melanoma have been completely rewritten, with the introduction of targeted therapies with BRAF and MEK inhibitors (Larkin et al., 2014; Long et al., 2014; Robert et al., 2016), and immunotherapy with the anti CTLA-4 ipilimumab (Hodi et al., 2010) and the anti-PD-1 nivolumab (Robert et al., 2015) and pembrolizumab (Schachter et al., 2017). Here, BRAF is linked to melanoma.